Duloxetine is not an MAOI. It belongs to a completely different class of antidepressants called serotonin and norepinephrine reuptake inhibitors (SNRIs). While both drug classes affect some of the same brain chemicals, they work through different mechanisms and carry very different risk profiles.
How Duloxetine Actually Works
Duloxetine blocks the reabsorption of two chemical messengers in the brain: serotonin and norepinephrine. When these chemicals are released between nerve cells, they normally get recycled back into the cell that sent them. Duloxetine slows that recycling process, keeping more serotonin and norepinephrine active in the gap between nerve cells. This is what “reuptake inhibition” means.
MAOIs take a fundamentally different approach. Instead of blocking reabsorption, they disable an enzyme called monoamine oxidase, which is responsible for breaking down serotonin, norepinephrine, and dopamine. By disabling this enzyme, MAOIs prevent these chemicals from being destroyed, which also increases their levels in the brain. The four MAOIs currently approved for depression in the U.S. are isocarboxazid, phenelzine, tranylcypromine, and selegiline.
So both drug types raise levels of serotonin and norepinephrine, but they do it through entirely separate pathways. This distinction matters because it affects side effects, dietary restrictions, and which medications you can safely combine with each one.
Why the Distinction Matters for Side Effects
SNRIs like duloxetine are generally better tolerated than MAOIs. One major reason: duloxetine doesn’t bind significantly to the receptor types (muscarinic, histaminergic, and alpha-adrenergic) that cause many of the troublesome side effects associated with older antidepressants. MAOIs and tricyclic antidepressants do interact with those receptors, leading to problems like sedation, weight gain, dizziness, dry mouth, and urinary hesitation at the doses typically needed for treatment.
MAOIs also come with strict dietary requirements. Because monoamine oxidase breaks down tyramine (a substance found in aged cheeses, cured meats, fermented foods, and certain wines), blocking that enzyme lets tyramine build up to dangerous levels. This can trigger sudden, severe spikes in blood pressure. Duloxetine has no dietary restrictions of this kind.
That said, SNRIs aren’t side-effect free. Duloxetine can cause nausea, dry mouth, drowsiness, and fatigue. Venlafaxine, another SNRI, carries a risk of sustained high blood pressure at higher doses.
Why You Cannot Take Both Together
Even though duloxetine isn’t an MAOI, combining the two is dangerous. Taking duloxetine and an MAOI at the same time floods the brain with far too much serotonin, potentially triggering a condition called serotonin syndrome. Duloxetine’s prescribing information specifically lists concurrent or recent MAOI use (within two weeks) as a contraindication.
Serotonin syndrome can range from mild to life-threatening. Early signs often include agitation, restlessness, rapid heartbeat, and diarrhea. As it progresses, symptoms can escalate to muscle twitching and rigidity (especially noticeable in the legs), dilated pupils, heavy sweating, high blood pressure, and fever. In severe cases, it can cause seizures and dangerously high body temperature. The neuromuscular signs, particularly exaggerated reflexes and involuntary muscle jerking, are the hallmark features that distinguish serotonin syndrome from other drug reactions.
Switching Between the Two
If you’re transitioning from one of these medications to the other, a waiting period is required to let the first drug clear your system before starting the second.
- From an MAOI to duloxetine: A 14-day drug-free washout period is necessary. MAOIs irreversibly disable the monoamine oxidase enzyme, so your body needs about two weeks to produce enough new enzyme to restore normal function.
- From duloxetine to an MAOI: You need to taper off duloxetine, then wait at least 7 days before cautiously starting a low-dose MAOI.
These timelines exist specifically to prevent the overlap that causes serotonin syndrome. The waiting periods differ because the two drug classes leave the body at different rates and affect brain chemistry through different mechanisms. MAOIs require the longer gap because the enzyme they disable has to be rebuilt from scratch, not just cleared from the bloodstream.